HeartBeam Inc. (NASDAQ: BEAT) reported second-quarter 2026 financial and operational results, highlighting significant progress across its heart attack detection program, 12-lead ECG extended wear patch, and initial commercial launch. The company completed enrollment of 134 patients in its ALIGN-ACS pilot study ahead of schedule, with full results expected to be presented at TCT 2026. Additionally, HeartBeam surpassed 50% enrollment in its 500-patient HEADSTART-ACS pilot study, a key milestone for the program.
The company also completed a working prototype of its 12-lead ECG extended wear patch, a critical step toward expanding its product portfolio. HeartBeam has signed multiple commercial agreements across four targeted U.S. geographies, shipped its first orders, and onboarded initial patients, marking the start of its commercial rollout.
Financially, HeartBeam reported a second-quarter net loss of $5 million, or $0.10 per basic and diluted share, compared with a net loss of $5 million, or $0.15 per share, in the same period last year. As of June 30, 2026, the company held cash, cash equivalents, and restricted cash totaling $8.8 million. HeartBeam expects full-year 2026 net operating cash outflow to be below $14 million, which, combined with its current cash position, extends its cash runway into 2027.
These developments underscore HeartBeam's commitment to transforming cardiac care. The company is developing a cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable use, enabling physicians to identify cardiac health trends and acute conditions outside of medical facilities. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to its technology.
The ALIGN-ACS and HEADSTART-ACS studies are pivotal in validating the system's ability to detect heart attacks, which could significantly improve patient outcomes by enabling earlier diagnosis and treatment. The completion of the ALIGN-ACS enrollment ahead of schedule and the advancement of HEADSTART-ACS highlight the efficiency and promise of HeartBeam's clinical development.
The initial commercial launch, with agreements in four U.S. geographies and first orders shipped, represents a tangible step toward market penetration. As HeartBeam continues to execute on its strategic plan, the extension of its cash runway into 2027 provides financial stability to support ongoing clinical trials and commercialization efforts.
For more information about HeartBeam and its technology, visit the company's newsroom at https://ibn.fm/BEAT and its cleared indications for use at https://www.heartbeam.com/indications.
